STOCK TITAN

Quoin Pharmaceuticals, Ltd. - $QNRX STOCK NEWS

Welcome to our dedicated page for Quoin Pharmaceuticals, Ltd. news (Ticker: $QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals, Ltd. stock.

Quoin Pharmaceuticals Ltd. (symbol: QNRX) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing therapeutic products for rare and orphan diseases. Founded with a commitment to addressing unmet medical needs, Quoin focuses on innovating treatments that can make a significant impact on patients’ lives.

Quoin’s research and development pipeline includes potential treatments for a range of conditions such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa. Their work is particularly focused on Netherton Syndrome, a rare genetic disorder characterized by defective skin barrier function.

Recently, Quoin made significant strides in its clinical studies for Netherton Syndrome. Protocol amendments, based on initial positive data, were approved by the FDA and include increasing study sizes, modifying dosing frequencies, and broadening eligibility criteria. These changes aim to enhance the potential for a successful outcome.

Furthermore, Quoin expanded its intellectual property portfolio by filing both US and international patent applications for a novel combination product to treat Netherton Syndrome. They are also exploring additional patent opportunities related to the clinical and manufacturing aspects of their products.

Financially, Quoin has strengthened its position through a successful public offering and the execution of an equity line of credit arrangement, extending their cash runway into late 2025. This financial stability supports the company as it pursues key milestones in its development pipeline.

Under the leadership of Dr. Michael Myers, Quoin Pharmaceuticals is poised to make significant advancements in the field of rare and orphan disease treatments. The company continues to engage with the investment community and stakeholders through various communication channels, ensuring transparency and building investor confidence.

To stay updated on Quoin Pharmaceuticals' latest developments, visit their website or follow them on LinkedIn.

Rhea-AI Summary

Quoin Pharmaceuticals (NASDAQ: QNRX) has signed a research agreement with University College Cork (UCC) to develop novel topical formulations of Rapamycin (sirolimus) targeting rare and orphan diseases. The focus is on using UCC's proprietary dissolvable microneedle technology to enhance local drug delivery and therapeutic effectiveness. This research program, funded by Quoin, aims to create innovative treatments for diseases lacking approved therapies. Quoin will have the option to advance clinical development without paying upfront fees or royalties. UCC's microneedles dissolve upon skin penetration, offering advantages like painless administration and minimal trauma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
none
-
Rhea-AI Summary

Quoin Pharmaceuticals, a specialty pharmaceutical company, announced positive clinical developments in Netherton Syndrome, including FDA clearance for teen recruitment and protocol amendments for ongoing studies. The company extended its cash runway into late 2025 and expanded its patent portfolio. Financially, Quoin had $14.7 million in cash, with a net loss of $2.3 million for the first quarter of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
-
Rhea-AI Summary

Quoin Pharmaceuticals (QNRX) will reveal its first quarter 2024 financial results on May 9th, 2024. The announcement will cover operational progress and financial highlights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.34%
Tags
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (QNRX) reports positive initial clinical data for QRX003 in Netherton Syndrome study, lowers enrollment age, and extends cash runway into 2025. Financially, the company had $10.7 million in cash by December 31, 2023, with a net loss of $2.0 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.79%
Tags
-
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the release of its fourth quarter and 2023 financial results on March 13, 2024. The company will host a conference call on March 14, 2024, to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. announced a public offering of 4,062,500 ordinary shares at $1.60 per American Depositary Share, raising approximately $6.5 million. The offering includes Series D and Series E warrants with exercise prices of $1.60 per share, expiring in two and five years, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.28%
Tags
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. receives FDA clearance to include teen patients in clinical trials for Netherton Syndrome drug QRX003, expanding eligible subjects and potentially expediting recruitment. This marks the first time non-adult subjects are included in studies under an open IND, a significant advancement for the Netherton community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
-
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome. The product combines a serine protease inhibitor with an anti-inflammatory agent in a proprietary topical formulation. Quoin anticipates patents to extend to at least 2044, further strengthening their industry-leading position. They are currently enrolling patients in two clinical trials for the potential treatment of Netherton Syndrome with their QRX003 topical lotion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has received FDA clearance to implement protocol amendments to its two ongoing clinical trials for QRX003, a potential treatment for Netherton Syndrome. Positive initial data and a clean safety profile have led to an increase in the size of both trials, elimination of the lower dose, and a change in dosing frequency to twice-daily. Dr. Michael Myers, CEO of Quoin, expressed optimism for a compelling data set and potential regulatory approval for QRX003.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) reported positive clinical data for QRX003 in the ongoing open-label Netherton Syndrome study. The results showed positive benefits across various clinical endpoints, including pruritus, Investigator skin scoring system, and patient global assessment. No safety concerns have been observed, and the company's cash runway is expected to extend through the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags

FAQ

What is Quoin Pharmaceuticals?

Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases.

What diseases is Quoin Pharmaceuticals targeting?

Their pipeline includes treatments for Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa.

What are the recent achievements of Quoin Pharmaceuticals?

They have made significant protocol amendments in their Netherton Syndrome studies, expanded their patent portfolio, and strengthened their financial position.

Who is leading Quoin Pharmaceuticals?

Dr. Michael Myers, Ph.D., serves as the CEO of Quoin Pharmaceuticals.

How can I stay updated on Quoin Pharmaceuticals' news?

You can visit their official website or follow them on LinkedIn for the latest updates.

What is Netherton Syndrome?

Netherton Syndrome is a rare genetic disorder characterized by defective skin barrier function. Quoin is focusing significant research efforts on this condition.

What financial strategies has Quoin Pharmaceuticals implemented recently?

They extended their cash runway into late 2025 through a public offering and an equity line of credit arrangement.

What is unique about Quoin Pharmaceuticals' approach?

Quoin focuses on developing high-impact treatments for rare diseases, with an extensive pipeline and strategic clinical studies.

Are Quoin Pharmaceuticals' statements forward-looking?

Yes, many of their statements are forward-looking and subject to risks and uncertainties, as detailed in their SEC filings.

Where is Quoin Pharmaceuticals listed?

Quoin Pharmaceuticals’ American Depositary Shares are traded on the stock market under the symbol QNRX.

Quoin Pharmaceuticals, Ltd.

Nasdaq:QNRX

QNRX Rankings

QNRX Stock Data

2.73M
3.67M
0.53%
2.3%
0.31%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
KFAR SABA